Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib ; volume:13 ; number:1 ; day:20 ; month:9 ; year:2023 ; pages:1-7 ; date:12.2023
Scientific reports ; 13, Heft 1 (20.9.2023), 1-7, 12.2023
- Creator
-
Spinelli, Francesca Romana
Garufi, Cristina
Mancuso, Silvia
Ceccarelli, Fulvia
Truglia, Simona
Conti, Fabrizio
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-42371-z
- URN
-
urn:nbn:de:101:1-2024020112450208336391
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Spinelli, Francesca Romana
- Garufi, Cristina
- Mancuso, Silvia
- Ceccarelli, Fulvia
- Truglia, Simona
- Conti, Fabrizio
- SpringerLink (Online service)
Other Objects (12)
Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis
Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience
Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
Effects of tofacitinib on bone turnover markers and bone modulators in patients with rheumatoid arthritis
Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis
Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience
Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
Effects of tofacitinib on bone turnover markers and bone modulators in patients with rheumatoid arthritis
Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis
Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience
Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
Effects of tofacitinib on bone turnover markers and bone modulators in patients with rheumatoid arthritis
Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation